ChannelLife New Zealand logo
Industry insider news for New Zealand's technology resellers
Story image

James Arnold from Dell New Zealand shares his cancer story

By Contributor
Wed 27 Oct 2021

Story reposted with permission from The Medicine Gap and James Arnold. Techday's editors have modified the headline for clarity.

As of Tuesday 26th October, Dell Technologies' Medium Business ANZ director and general manager, James Arnold, is in a hospital prepping for a stem cell transplant. In the process, he will lose his immunity and be incapable of fighting off any bacteria or virus. He’ll be kept in isolation in a pressure room to make sure air can leave the room, but germs can’t filter in. 

Delta adds another layer of complexity to an already invasive procedure.

“It’s up to the doctors to keep me alive. Sadly, we’re living in a world with a virulent bug going around that’s trying to hurt us. It throws a bit of a spanner in the works.”

James isn’t sure how long he’ll be in hospital, but he’s been told it could be up to a month.

“How do I feel? Honestly? I’m terrified. Absolutely terrified,” he says.

James is 51 years old, married to Carlene with two teenage daughters. He’s a successful, well paid, highly regarded IT consultant and by his own admission he “lives well” on Auckland’s North Shore. He keeps fit playing squash and, when his health allows, he can usually squeeze in a few games a week.

“I love it, it’s a great game.”

In March, James felt a bit tired but otherwise life was going well. Really well. The following month, a phone call from a doctor turned his life on its head.

“It’s not until you get a diagnosis like this that you realise cancer isn’t a singular disease. It affects everyone around you. It’s been incredibly tough on my wife and when we told our two daughters…. well, that was a very tough day. Very tough.”

James says, in hindsight, he can now recognise the symptoms.

“I was struggling to keep up when I played squash. I thought it was probably because I was getting on a bit, so I put it down to age.”

James assumed the swollen lymph nodes under his jaw were the start of a newly acquired double chin, but it was a numb sensation in his bottom lip that ultimately led to a GP’s appointment, and a diagnosis.

“My bottom lip would go numb if I sat on the couch and leaned back. It was the weirdest thing. And if I went to sleep on my back, I would wake up with the same sensation.”

He began to get strong cramps in the upper part of his abdomen and, after a stint on Google, he thought he might have gallstones. His GP agreed and sent him for an ultrasound.

“That was when we started to find out what was going on.”

The sonographer couldn’t get a clear view of James’s gallbladder and sought a second opinion. Then a third specialist was called into the room.

“I knew at that stage the news probably wasn’t going to be good.”

They found a lump in James’s abdomen, later identified as a 13 x 8 x 11 cm mass of swollen lymph nodes. It was pressing on either nerves or his blood supply, causing the numbness in James’s face. His spleen was double its normal size, and tests showed that 80% of his bone marrow was cancerous.

James Arnold was diagnosed with Mantle Cell Lymphoma, a form of blood cancer that develops in the lymph nodes.

“I’m young to have this cancer and I guess I’m lucky because it’s the indolent form which means it grows and spreads slowly. It can switch to aggressive, but for the moment, it’s the slow version.”

Since his diagnosis in April, James has undergone surgery, and six long and taxing cycles of chemotherapy. Each session is around three to four weeks apart. Ultimately, it’s hoped the chemotherapy will destroy the cancer cells and this week, after months of treatment, a CT scan showed no evidence of disease.

James is optimistic but also realistic. There is no cure for Mantle Cell Lymphoma. It will come back.

“That’s why we do the stem cell transplant. It will get any cancer we’ve missed in the bone marrow, and hopefully put me into remission for somewhere between 2 and 10 years.”

Six weeks ago, in readiness for the transplant, James was hooked up to a machine for hours on end, and his blood was siphoned to remove his stem cells.

“It was a hard day. I came home that night and I cried. It broke me.”

This week will be a lot tougher.

James will start ‘consolidation therapy’ which means he will undergo six intensive sessions of chemotherapy, positioned 12 hours apart. He’ll suck on ice to ease the onset of an ulcerated mouth, and it will hopefully quell any nausea and gastro-intestinal upheaval.

“By the fourth day I’ll be feeling pretty average. The poison will be all through my system, but it should destroy any last cells of cancer.”

The following week, James’s stem cells will be defrosted and infused back into his body, eventually restoring his immune system and his body’s ability to produce blood cells and fight infection.

It is the standard treatment for Mantle Cell Lymphoma and is performed all over the world. Usually, when the cancer returns in the years ahead, patients are treated with what’s called a ‘second line’ treatment.

“…and this is sadly where the story takes a turn for the worse in New Zealand.”

New Zealand doesn’t fund a second line treatment.

For more than half a decade, a drug called a ‘BTK Inhibitor’ has been used to target and kill relapsed Mantle Cell Lymphoma. It targets cancer cells and inhibits their growth. In James’s case, it’s likely he would be treated with Ibrutinib which has proven highly effective at putting the cancer back into remission.

It’s a drug that is publicly funded all over the developed world, but it’s not funded in New Zealand.

The list price for Ibrutinib is almost $15k per month although Pharmac, New Zealand’s monopolistic drug-buying agency, is a good negotiator. It seldom, if ever, pays the list price for a drug.

In 2015, a funding application for Ibrutinib was lodged and approved for use by Medsafe, and was recommended for funding by Pharmac’s expert team of oncologists.

Six years on, Ibrutinib remains on Pharmac’s list of unfunded medicines. Tragically, New Zealand now sits at the bottom of the developed world for access to modern medicines, and has the lowest per capita pharmaceutical spend of the OECD.

Pharmac has been chronically underfunded by successive governments for more than a decade, and New Zealanders are now paying with their lives.

For Carlene, it has been the most brutal of realisations. She is concentrating on supporting James throughout his treatment but is fearful of the implications of a relapse.

“This is very raw to me. To put a price on a life in this way, it’s so distressing.”

“I struggle to describe the emotions I feel. On every single level this is wrong. When you see where the Government is putting money and yet they don’t fund modern medicines to treat New Zealanders, to help people… did we get here?”

Carlene says if she has to pack up her family and move to Brisbane, she will, but it will come at a huge emotional cost.

“If James relapses and we leave New Zealand, we lose a lot. Our friends, our family, our support. It’s immense. It’s overwhelming to think about packing up our lives when the cancer comes back.”

James, despite his diagnosis, describes himself as “lucky” because he has Australian citizenship. Across the Tasman, the second line treatments for this disease are fully funded, but he says moving to Australia would be the last resort. 

“I live here. I’ve raised my family here, I love it. I’ve paid a considerable amount of tax in this country, and I contribute to the economy. I don’t want to relocate to Australia. This is my home.”

It’s believed up to 90 New Zealanders suffer from Mantle Cell Lymphoma and while James is grateful that Australia provides him with a lifeline, he believes every New Zealander should be able to access modern treatments.

“You only find out how far behind we are when you’re staring down the barrel of a gun. Modern medicines are a part of everyday society. You have to look after your citizens.”

Show your support.

Please share James Arnold's story.

New Zealand needs access now to modern medicines to treat Mantle Cell Lymphoma.

Related stories
Top stories
Story image
OHI Data Navigator recognised by IDC for APAC contribution
IDC has chosen OHI Data Navigator as the best Asia Pacific Smart City project under its 2022 Smart City Asia/Pacific Awards (SCAPA) category under the Public Health and Social Services category.
Story image
UNIQLO operator chooses Adyen for multiple market payments
The operator of UNIQLO, Fast Retailing, has selected Adyen to power payments for its in-store and online checkout in multiple markets.
Story image
ABI Research
75% of 5G networks to advance to 5G-Advanced by 2030
5G-advanced is set to launch in 2025, and 75% of 5G networks will upgrade by 2030, according to ABI Research. 
Story image
Online bullying, harassment skyrockets since COVID outbreak
Harmful content reports have risen by over 25% since the outbreak of the COVID pandemic, according to Netsafe.
Story image
Artificial Intelligence
Vectra AI named as AWS security competency partner
Threat detection and response company Vectra AI has announced that it has become an Amazon Web Services Security Competency Partner.
Story image
Hybrid Cloud
Advent One acquires Layer 8 Networks, complements hybrid cloud offering
The acquisition comes at a time of surging demand in hybrid cloud, network virtualisation and network security.
Story image
Sony releases a new gaming gear brand for PC gamers
Sony has unveiled INZONETM, a new gaming gear brand for PC gamers that makes gaming more immersive and offers greater gaming ability.
Story image
SAS wins Microsoft ISV 2022 Partner of the Year award
"We formed the SAS and Microsoft strategic partnership with a shared goal of making it easier for customers to drive better decisions in the cloud."
Story image
Monitors are an excellent incentive for getting employees back
The pandemic has taught us that hybrid working is a lot easier than we would’ve thought, so how can the office be made to feel as comfortable as home? The answer could be staring you in the face right now.
Story image
Mergers and Acquisitions
SAS acquires Kamakura to propel risk technology innovation
Underscoring SAS growth in the domain-specific solutions space, the acquisition will enable SAS to greatly enhance the breadth of its risk solutions portfolio. 
Story image
Artificial Intelligence
Eight top DevSecOps trends to support IT innovation in 2022
The use of DevSecOps practices is growing, as it is increasingly seen as the best way to produce high-quality and secure code. So what are the current trends?
Story image
Digital innovation could shape the future of NZ - Microsoft
With cloud technologies available to more people around the world than ever before, it is not only businesses who will benefit from using them.
Story image
Without trust, your security team is dead in the water
The rise of cyberattacks has increased the need for sound security that works across any type of business, but with any change, buy-in is essential. Airwallex explains why.
Story image
Hands-on review: Phillips Hue starter kit
The set-up was one of the simplest I have ever had to do. It is also where the products shine. I was able to connect the bridge, the three lightbulbs and the strip within 10 min.
Story image
Internet of Things
ManageEngine wins big in IDC MarketScape assessment
ManageEngine's Endpoint Central service has been recognised as a leader by IDC MarketScape in several categories including Internet of Things device deployments and UEM software for SMEs.
Story image
Supply chain
Supply chains continue to be disrupted, enterprises embrace circular economy
“Businesses urgently need to find a solution that can help them to manage this disruption, and transition to a circular economy."
Story image
Artificial Intelligence
Siemens expands NVIDIA partnership for industrial metaverse
Siemens is expanding its partnership with NVIDIA to enable the industrial metaverse and increase the use of AI-driven digital twin technology.
Story image
Cloudian, Vertica to deliver on-premise data warehouse platform
"We’re enabling our customers to capitalise on a leading object storage platform and maximise the value of their digital assets.”
Story image
FIDO Alliance releases guidelines for optimising UX with FIDO Security Keys
The new guidelines aim to accelerate multi-factor authentication deployment and adoption with FIDO security keys.
Story image
Cyber Criminal
Identity and access: the fight is on
Blue team defenders are used to protecting our data, applications, and users with access controls and other security mechanisms, which is why attacks like this are especially challenging when they target identity and access control systems.
Story image
Up to $2.4 million shortfall in the collapse of IndeServe
We delve into the liquidators first report on long-standing networking service provider IndeServes collapse.
Story image
Data Protection
How secure is accounting software data in Aotearoa?
A recent Xero study found ICT spending for NZ businesses has increased 25% compared to pre-pandemic levels, so how safe is accounting software?
Story image
Examining the future of ransomware threats with Vectra’s CTO
As customers' valuable data move to the cloud, so will ransomware. What is the current landscape and what do we need to know?
Story image
Financial results
Margins & revenues up at New Zealand arm of Acer Computer
We look at the local financial statements of Taiwanese manufacturer Acer Computer Inc.
Story image
Hands-on review: GoDice
In a world where we’re more connected than ever to our smart devices, startup company Particula believes that its innovative product GoDice is the answer to getting everyone reconnected with one another - by turning that smart device into an interactive board game.
Story image
Hands-on review – CleanMyMac X utility for macOS
We get hands-on with a useful utility that macOS users never thought they needed but probably do.
Story image
Tech and data’s role in the changing face of compliance
Accenture's study found that 93% of respondents agree or strongly agree new technologies such as AI and cloud make compliance easier.
Story image
Businesses unprepared to defend against ransomware attacks
Ransomware attacks continue to impact organisations worldwide with high costs, but businesses are still largely unprepared.
Story image
Evonik relies on Getac F110 tablet to control autonomous robot
The aim of the project is to evaluate the practicality of an automated robotic maintenance and inspection solution in the chemical industry.
Story image
NEC expands Open RAN ecosystem with Aspire Tech acquisition
With its agreement to acquire Aspire Technology, NEC Corporation has further increased its capacity to deliver End-to-End Open RAN ecosystems.
Story image
Tech job moves
Tech job moves - Bitdefender, Cohesity, Fortinet & MODIFI
We round up all job appointments from June 27-30, 2022, in one place to keep you updated with the latest from across the tech industries.
Story image
BT builds on Equinix partnership with new cloud offering
BT has launched a next-generation cloud connectivity offering extending its global network into strategic carrier-neutral facilities (CNFs) and building on its existing partnership with Equinix.
Story image
Video: 10 Minute IT Jams - An update from Paessler
Sebastian Krüger joins us today to discuss how unified infrastructure monitoring enables MSPs to seamlessly deliver services to their clients.
Story image
Identity and Access Management
Ping Identity named a Leader in Access Management
Ping Identity has been named a leader in the 2022 KuppingerCole Leadership Compass report for Access Management. 
Story image
Digital Transformation
Retailers must invest in new tech to keep up with online shopping demand
There's a higher demand for more purchasing opportunities at our fingertips, as well as greater expectations when it comes to the online customer experience."
Story image
Internet of Things
Large enterprises propel 5G industrial IoT market
Large enterprises are propelling the 5G industrial Internet of Things market, according to a recently published report from Future Market Insights.
Story image
Artificial Intelligence
Dynatrace extends automatic release validation capabilities
Dynatrace has extended its platform release validation capabilities to improve user experience at every stage of the software development lifecycle.
Story image
ASI Solutions named finalist of Microsoft Surface Partner of the Year
"ASI Solutions has a strong Microsoft focus, building value by helping customers maximise investment in modern workplace solutions."
Story image
Video: 10 Minute IT Jams - An update from CyberArk
Olly Stimpson joins us today to discuss the importance of MSP programmes and how MSP partners are experiencing success with CyberArk.
Story image
How organisations can mitigate IoT and IIoT security risks
IoT and IIoT come with inherent risks because they are often deployed faster than they can be secured, putting organisations in danger of cyber threats. Here are tips on how to mitigate those risks.
Story image
Dark web
Cybercrime in Aotearoa: How does New Zealand law define it?
‘Cybercrime’ is a term we hear all the time, but what exactly is it, and how does New Zealand define it in legal terms?
Story image
Web Development
Whitecliffe fosters careers for the future of tech
Do you want a career in Information Technology, Networking, Web Development, Software Development, or are you looking to upskill?
Story image
Azure-based technology asBuilt signals better BIM outcomes in NZ
The Microsoft Azure-based asBuilt intelligence hub is helping Kiwi businesses accelerate their building information management potential.
Story image
Great Resignation
New SAP study uncovers impact of 'the great resignation'
Coined in 2021, the phrase 'the great resignation' refers to millions of employees globally leaving their jobs. The phenomenon is real and impacting SMEs.